No abstract

No abstract

IMPORTANCEThe first-line treatment for patients with chronic spontaneous urticaria (CSU), which is divided into idiopathic and autoimmune subtypes, consists of H 1 -antihistamines. However, limited evidence guides the treatment of CSU after maximal therapy with antihistamines fails. Two randomized clinical trials suggest that dapsone may be a successful second-line therapy.OBJECTIVE To evaluate the efficacy and safety of dapsone therapy in patients with CSU.

No abstract

No abstract